{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:44:22Z","timestamp":1793198662126,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Breast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. Taxanes are the most used chemotherapeutic agents and are strictly connected to neurotoxicity. Taxane-induced neuropathy (TIN) significantly impacts patients\u2019 quality of life (QOL). Early identification and management of TIN could improve preventive strategies to preserve patients\u2019 QOL during and after breast cancer treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This prospective, observational study aimed to evaluate the taxane-induced neuropathy (TIN) in early breast cancer patients treated with weekly paclitaxel at an earlier stage and identify any correlation between TIN and QOL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from stage I-III breast cancer patients treated with taxane-based therapy between 2018 and 2022 were collected at the Medical Oncology Unit of the University Hospital of Cagliari. Peripheral neuropathy was evaluated using the NCI-CTCAE scale (National Cancer Institute, Common Terminology Criteria for Adverse Events) at every drug administration. In contrast, QOL was assessed using EORTC QLC-CIPN20 and FACT-Taxane questionnaire at baseline (T0), after 4\u00a0weeks (T1) and 12 (T2) weeks of treatment. Statistical analysis was performed to evaluate the correlation between neurotoxicity and QOL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Neurotoxicity incidence peaked at the third, fourth, and sixth week of treatment, with patients reporting grade 1 and 2 neurotoxicity. Simultaneously with increasing doses of paclitaxel, significant differences in QOL were observed in early treatment cycles relating to TIN presentation. Patients with higher neurotoxicity grades reported lower QOL scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite the absence of effective treatments to prevent paclitaxel-induced neurotoxicity, symptoms are managed through dosage reduction, delay, or treatment interruption. Future research should focus on identifying neuroprotective measures to avoid an irreversible decline in the quality of life for breast cancer survivors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08908-2","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:01:33Z","timestamp":1728345693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Early taxane exposure and neurotoxicity in breast cancer patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Erika","family":"Cimbro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Dess\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pina","family":"Ziranu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Donisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Spanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pozzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Murgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Codipietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Palmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Semonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Sardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Finco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"4","key":"8908_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"Global Burden of Disease Cancer Collaboration","year":"2015","unstructured":"Global Burden of Disease Cancer Collaboration (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505\u2013527. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0735","journal-title":"JAMA Oncol"},{"key":"8908_CR2","unstructured":"Global Cancer Observatory: Cancer Today. https:\/\/gco.iarc.fr\/today\/home"},{"issue":"4","key":"8908_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/cncr.20335.abs","volume":"94","author":"A de Matteis","year":"2002","unstructured":"de Matteis A, Nuzzo F, D\u2019Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F (2002) Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94(4):895\u2013901. https:\/\/doi.org\/10.1002\/cncr.20335.abs","journal-title":"Cancer"},{"issue":"3","key":"8908_CR4","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(3):e00149. https:\/\/doi.org\/10.1002\/prp2.149. Erratum in: Pharmacol Res Perspect. 2019 Dec;7(6):e00549","journal-title":"Pharmacol Res Perspect"},{"issue":"13","key":"8908_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","volume":"17","author":"J Anampa","year":"2015","unstructured":"Anampa J, Makower D, Sparano JA (2015) Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 17(13):195. https:\/\/doi.org\/10.1186\/s12916-015-0439-8","journal-title":"BMC Med"},{"issue":"9","key":"8908_CR6","doi-asserted-by":"publisher","first-page":"e44105","DOI":"10.2196\/44105","volume":"8","author":"D Kang","year":"2023","unstructured":"Kang D, Kim S, Kim H, Lee M, Kong SY, Chang YJ, Sim SH, Kim YJ, Cho J (2023) Surveillance of symptom burden using the patient-reported outcome version of the common terminology criteria for adverse events in patients with various types of cancers during chemoradiation therapy: real-world study. JMIR Public Health Surveill 8(9):e44105. https:\/\/doi.org\/10.2196\/44105","journal-title":"JMIR Public Health Surveill"},{"key":"8908_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuropharm.2013.08.016","volume":"76 Pt A","author":"E Gornstein","year":"2014","unstructured":"Gornstein E, Schwarz TL (2014) The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology 76 Pt A:175\u201383. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.016","journal-title":"Neuropharmacology"},{"issue":"8","key":"8908_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lant\u00e9ri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, EORTC Quality of Life Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2005.02.012","journal-title":"Eur J Cancer"},{"issue":"4","key":"8908_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(05)70094-2","volume":"6","author":"A Montero","year":"2005","unstructured":"Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumors: a systematic review of clinical data. Lancet Oncol 6(4):229\u2013239. https:\/\/doi.org\/10.1016\/S1470-2045(05)70094-2","journal-title":"Lancet Oncol"},{"issue":"14","key":"8908_CR10","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1111\/bph.15086","volume":"177","author":"R da Costa","year":"2020","unstructured":"da Costa R, Passos GF, Quint\u00e3o NLM, Fernandes ES, Maia JRLCB, Campos MM, Calixto JB (2020) Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol 177(14):3127\u20133146. https:\/\/doi.org\/10.1111\/bph.15086","journal-title":"Br J Pharmacol"},{"key":"8908_CR11","first-page":"107","volume":"15","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107\u2013115","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"10","key":"8908_CR12","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","volume":"16","author":"AD Seidman","year":"1998","unstructured":"Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16(10):3353\u20133361. https:\/\/doi.org\/10.1200\/JCO.1998.16.10.3353. Erratum in: J Clin Oncol. 2006 May 10;24(14):2220. Albanel, J [corrected to Albanell, J]","journal-title":"J Clin Oncol"},{"issue":"21","key":"8908_CR13","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31(21):2699\u20132707. https:\/\/doi.org\/10.1200\/JCO.2013.49.1514","journal-title":"J Clin Oncol"},{"issue":"1","key":"8908_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/SPC.0000000000000684.]","volume":"18","author":"DL Hertz","year":"2024","unstructured":"Hertz DL (2024) Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy. Curr Opin Support Palliat Care 18(1):30\u201338. https:\/\/doi.org\/10.1097\/SPC.0000000000000684.]","journal-title":"Curr Opin Support Palliat Care"},{"issue":"6","key":"8908_CR15","first-page":"455","volume":"6","author":"SM Swain","year":"2008","unstructured":"Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6(6):455\u2013467","journal-title":"Clin Adv Hematol Oncol"},{"key":"8908_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1200\/jco.2004.22.90140.512","volume":"22","author":"AD Seidman","year":"2004","unstructured":"Seidman AD et al (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. JCO 22:512\u2013512. https:\/\/doi.org\/10.1200\/jco.2004.22.90140.512","journal-title":"JCO"},{"issue":"16","key":"8908_CR17","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663\u20131671. https:\/\/doi.org\/10.1056\/NEJMoa0707056. Erratum in: N Engl J Med. 2008 Jul 3;359(1):106. Erratum in: N Engl J Med. 2009 Apr 16;360(16):1685","journal-title":"N Engl J Med"},{"issue":"8","key":"8908_CR18","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/0959-8049(94)90459-6","volume":"30A","author":"JM Van Gerven","year":"1994","unstructured":"Van Gerven JM, Moll JW, van den Bent MJ, Bontenbal M, van der Burg ME, Verweij J, Vecht CJ (1994) Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30A(8):1074\u20131077. https:\/\/doi.org\/10.1016\/0959-8049(94)90459-6","journal-title":"Eur J Cancer"},{"issue":"24","key":"8908_CR19","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"SE Jones","year":"2005","unstructured":"Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542\u20135551. https:\/\/doi.org\/10.1200\/JCO.2005.02.027","journal-title":"J Clin Oncol"},{"issue":"12","key":"8908_CR20","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","volume":"17","author":"K Shimozuma","year":"2009","unstructured":"Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483\u20131491. https:\/\/doi.org\/10.1007\/s00520-009-0613-7","journal-title":"Support Care Cancer"},{"issue":"12","key":"8908_CR21","doi-asserted-by":"publisher","first-page":"1005083","DOI":"10.3389\/fonc.2022.1005083","volume":"10","author":"L Schwab","year":"2023","unstructured":"Schwab L, Visovsky C (2023) Psychological distress and quality of life in breast cancer survivors with taxane-induced peripheral neuropathy: a scoping review. Front Oncol 10(12):1005083. https:\/\/doi.org\/10.3389\/fonc.2022.1005083","journal-title":"Front Oncol"},{"issue":"3","key":"8908_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","volume":"51","author":"L Eckhoff","year":"2015","unstructured":"Eckhoff L, Knoop A, Jensen MB, Ewertz M (2015) Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 51(3):292\u2013300. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.024","journal-title":"Eur J Cancer"},{"issue":"14","key":"8908_CR23","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/cam4.3129","volume":"9","author":"K Bennedsgaard","year":"2020","unstructured":"Bennedsgaard K, Ventzel L, Themistocleous AC, Bennett DL, Jensen AB, Jensen AR, Andersen NT, Jensen TS, Tankisi H, Finnerup NB (2020) Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. Cancer Med 9(14):5114\u20135123. https:\/\/doi.org\/10.1002\/cam4.3129","journal-title":"Cancer Med"},{"issue":"3","key":"8908_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10549-022-06670-9","volume":"195","author":"K Engvall","year":"2022","unstructured":"Engvall K, Gr\u00e9en H, Fredrikson M, Lagerlund M, Lewin F, \u00c5vall-Lundqvist E (2022) Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Res Treat 195(3):379\u2013391. https:\/\/doi.org\/10.1007\/s10549-022-06670-9","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"8908_CR25","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/ejn.14614","volume":"51","author":"JT Costa-Pereira","year":"2020","unstructured":"Costa-Pereira JT, Serr\u00e3o P, Martins I, Tavares I (2020) Serotoninergic pain modulation from the rostral ventromedial medulla (RVM) in chemotherapy-induced neuropathy: the role of spinal 5-HT3 receptors. Eur J Neurosci 51(8):1756\u20131769. https:\/\/doi.org\/10.1111\/ejn.14614","journal-title":"Eur J Neurosci"},{"issue":"13","key":"8908_CR26","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in Oncology (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u201367. https:\/\/doi.org\/10.1001\/jama.2013.2813","journal-title":"JAMA"},{"issue":"12","key":"8908_CR27","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2147\/JPR.S186107","volume":"3","author":"U Coffeen","year":"2019","unstructured":"Coffeen U, Sotomayor-Sobrino MA, Jim\u00e9nez-Gonz\u00e1lez A, Balcazar-Ochoa LG, Hern\u00e1ndez-Delgado P, Fres\u00e1n A, Plancarte-Sanchez R, Arias-Mu\u00f1\u00f3z SD, Ochoa-Aguilar A (2019) Chemotherapy-induced neuropathic pain characteristics in Mexico\u2019s National Cancer Center pain clinic. J Pain Res 3(12):1331\u20131339. https:\/\/doi.org\/10.2147\/JPR.S186107","journal-title":"J Pain Res"},{"issue":"16","key":"8908_CR28","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.3390\/ijms22168733","volume":"22","author":"T Kawashiri","year":"2021","unstructured":"Kawashiri T, Inoue M, Mori K, Kobayashi D, Mine K, Ushio S, Kudamatsu H, Uchida M, Egashira N, Shimazoe T (2021) Preclinical and clinical evidence of therapeutic agents for paclitaxel-induced peripheral neuropathy. Int J Mol Sci 22(16):8733. https:\/\/doi.org\/10.3390\/ijms22168733","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8908_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s11764-021-00997-w","volume":"17","author":"MAL Tanay","year":"2023","unstructured":"Tanay MAL, Armes J, Moss-Morris R, Rafferty AM, Robert G (2023) A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms. J Cancer Surviv 17(1):254\u2013277. https:\/\/doi.org\/10.1007\/s11764-021-00997-w","journal-title":"J Cancer Surviv"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08908-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08908-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08908-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T04:26:15Z","timestamp":1729311975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08908-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8908"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08908-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the study protocol, the ethical principles stated in the Declaration of Helsinki as well as those indicated in the International Conference on Harmonization (ICH) Note for Guidance on Good Clinical Practice (GCP; ICH E6, 1995), and all applicable regulatory requirements. All patients had to sign a written informed consent form before entering the study. Adequate information was given to eligible patients by the principal investigator or co-investigators at each participating Centre and in accordance with local regulations. Written informed consent to participate in the clinical study had to be given before any study-related activities were carried out. The declaration of informed consent was personally signed and dated by the subject and by the investigator\/person designated by the investigator to conduct the informed consent discussion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients provided written consent before engaging in study-related activities or providing study data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed an informed consent regarding the publishing of their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"709"}}